

TABLE 167: ANEMIA TREATMENT-NAIVE WITH EMERGING TREATMENTS: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + RBV12	PR48	0.71 (0.37 to 1.32)	-6.05 (-13.62 to 6.41)
SOF24 + RBV24		1.31 (0.52 to 2.57)	6.30 (-10.24 to 31.78)
SOF12 + LDV12		0.05 (0.02 to 0.13)	-19.53 (-22.72 to -16.31)
SOF8 + LDV8 + RBV8		0.34 (0.08 to 1.42)	-13.36 (-20.03 to 8.67)
SOF12 + LDV12 + RBV12		0.66 (0.35 to 1.21)	-6.92 (-14.09 to 4.28)
SOF24 + LDV24 + RBV24		0.58 (0.29 to 1.11)	-8.69 (-15.34 to 2.15)
T12 PR24-48 RGT q8		1.89 (1.33 to 2.52)	18.38 (6.82 to 30.63)
T12 PR24-48 RGT q12		2.08 (1.38 to 2.91)	22.31 (7.91 to 38.54)
T12 PR48 q8		1.19 (0.51 to 2.45)	3.89 (-10.56 to 29.05)
SOF12 + PR12		1.48 (0.82 to 2.42)	9.94 (-3.73 to 28.83)
SOF12 PR24-48 RGT		0.85 (0.39 to 1.75)	-3.02 (-13.21 to 14.51)
SIM12 PR24-48 RGT		0.82 (0.59 to 1.12)	-3.64 (-8.72 to 2.45)
B24 PR28-48 RGT		1.83 (1.27 to 2.45)	17.23 (5.57 to 29.69)
B44 PR48		1.58 (0.74 to 2.86)	12.00 (-5.53 to 37.15)
PR24		1.00 (0.40 to 2.09)	-0.08 (-12.85 to 22.27)
SOF24 + RBV (low dose) 24		0.86 (0.35 to 1.74)	-2.97 (-13.81 to 14.97)
PAR/RIT12 + OMB12 + DAS12		0.34 (0.15 to 0.74)	-13.50 (-18.37 to -5.35)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.39 (0.17 to 0.87)	-12.61 (-18.26 to -2.68)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV12 + SOF12		0.09 (0.00 to 1.01)	-18.32 (-22.60 to 0.18)
GRZ12 + ELB12		0.16 (0.05 to 0.52)	-17.32 (-21.57 to -9.34)
GRZ12 + ELB12 + RBV12		0.69 (0.23 to 1.99)	-6.46 (-16.71 to 19.67)
GRZ12 + ELB12 (50 mg q.d.)		0.09 (0.01 to 0.73)	-18.48 (-22.57 to -5.37)
GRZ18 + ELB18 (50 mg q.d.)		0.08 (0.00 to 1.50)	-18.49 (-22.77 to 10.43)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.23 (0.02 to 1.84)	-15.85 (-21.88 to 17.31)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.93 (0.08 to 3.90)	-1.39 (-19.68 to 59.98)
SOF24 + RBV24	SOF12 + RBV12	1.83 (0.72 to 4.42)	11.97 (-5.62 to 37.55)
SOF12 + LDV12		0.07 (0.03 to 0.20)	-13.41 (-25.79 to -6.39)
SOF8 + LDV8 + RBV8		0.50 (0.11 to 2.11)	-6.90 (-20.58 to 14.06)
SOF12 + LDV12 + RBV12		0.95 (0.40 to 2.16)	-0.72 (-13.85 to 11.41)
SOF24 + LDV24 + RBV24		0.82 (0.33 to 2.02)	-2.47 (-15.57 to 9.99)
T12 PR24-48 RGT q8		2.67 (1.31 to 5.47)	24.34 (7.44 to 38.81)
T12 PR24-48 RGT q12		2.94 (1.41 to 6.13)	28.24 (9.47 to 46.31)
T12 PR48 q8		1.70 (0.59 to 4.42)	9.89 (-9.04 to 34.88)
SOF12 + PR12		2.11 (1.08 to 4.04)	15.80 (1.61 to 32.93)
SOF12 PR24-48 RGT		1.23 (0.44 to 3.22)	3.18 (-12.75 to 21.38)
SIM12 PR24-48 RGT		1.17 (0.58 to 2.34)	2.45 (-10.52 to 11.29)
B24 PR28-48 RGT		2.60 (1.25 to 5.34)	23.15 (5.94 to 37.76)
B44 PR48		2.20 (0.87 to 5.54)	17.75 (-2.70 to 43.56)
PR24		1.41 (0.76 to 2.43)	5.79 (-3.54 to 21.76)
SOF24 + RBV (low dose) 24		1.20 (0.52 to 2.72)	2.91 (-9.78 to 19.80)
PAR/RIT12 + OMB12 + DAS12		0.49 (0.17 to 1.34)	-7.41 (-20.28 to 3.05)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.56 (0.19 to 1.55)	-6.22 (-19.91 to 5.22)
DCV12 + SOF12		0.14 (0.01 to 1.60)	-11.51 (-24.76 to 6.50)
GRZ12 + ELB12		0.22 (0.06 to 0.85)	-11.04 (-24.01 to -1.48)
GRZ12 + ELB12 + RBV12		0.96 (0.27 to 3.68)	-0.55 (-16.62 to 27.24)
GRZ12 + ELB12 (50 mg q.d.)		0.13 (0.01 to 1.21)	-12.16 (-24.77 to 2.21)
GRZ18 + ELB18 (50 mg q.d.)		0.12 (0.00 to 2.27)	-11.87 (-24.72 to 16.81)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.33 (0.02 to 2.88)	-9.11 (-22.46 to 23.40)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.35 (0.10 to 6.71)	4.95 (-18.06 to 64.85)
SOF12 + LDV12	SOF24 + RBV24	0.04 (0.01 to 0.13)	-25.86 (-51.42 to -9.58)
SOF8 + LDV8 + RBV8		0.27 (0.05 to 1.47)	-18.86 (-44.39 to 7.44)
SOF12 + LDV12 + RBV12		0.51 (0.21 to 1.35)	-13.00 (-38.22 to 4.68)
SOF24 + LDV24 + RBV24		0.45 (0.17 to 1.22)	-14.75 (-40.47 to 2.93)
T12 PR24-48 RGT q8		1.45 (0.67 to 3.76)	12.06 (-16.32 to 32.81)
T12 PR24-48 RGT q12		1.60 (0.71 to 4.23)	16.01 (-14.07 to 39.32)
T12 PR48 q8		0.93 (0.30 to 3.05)	-1.91 (-32.57 to 27.73)
SOF12 + PR12		1.14 (0.49 to 2.91)	3.77 (-23.89 to 27.15)
SOF12 PR24-48 RGT		0.67 (0.23 to 2.01)	-8.78 (-37.53 to 14.16)
SIM12 PR24-48 RGT		0.63 (0.30 to 1.64)	-9.86 (-35.74 to 7.21)
B24 PR28-48 RGT		1.40 (0.65 to 3.77)	10.66 (-17.12 to 31.99)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
B44 PR48		1.20 (0.44 to 3.72)	5.23 (-25.12 to 36.21)
PR24		0.77 (0.27 to 2.27)	-5.94 (-33.33 to 19.94)
SOF24 + RBV (low dose) 24		0.66 (0.33 to 1.34)	-8.82 (-28.56 to 5.54)
PAR/RIT12 + OMB12 + DAS12		0.26 (0.09 to 0.88)	-19.74 (-45.62 to -1.43)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.30 (0.10 to 1.00)	-18.86 (-44.73 to -0.04)
DCV12 + SOF12		0.08 (0.00 to 1.09)	-23.89 (-48.97 to 1.47)
GRZ12 + ELB12		0.12 (0.03 to 0.56)	-23.39 (-49.14 to -5.33)
GRZ12 + ELB12 + RBV12		0.53 (0.14 to 2.19)	-12.25 (-40.66 to 19.16)
GRZ12 + ELB12 (50 mg q.d.)		0.08 (0.00 to 0.76)	-24.20 (-50.69 to -3.58)
GRZ18 + ELB18 (50 mg q.d.)		0.07 (0.00 to 1.23)	-23.46 (-50.15 to 4.41)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.18 (0.01 to 1.78)	-20.12 (-48.35 to 14.45)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.75 (0.05 to 4.08)	-6.39 (-42.12 to 54.48)
SOF8 + LDV8 + RBV8	SOF12 + LDV12	6.62 (2.31 to 22.31)	5.93 (1.03 to 27.55)
SOF12 + LDV12 + RBV12		12.57 (4.95 to 37.77)	12.57 (6.09 to 23.66)
SOF24 + LDV24 + RBV24		10.86 (4.19 to 33.51)	10.72 (4.85 to 21.48)
T12 PR24-48 RGT q8		35.97 (14.02 to 98.96)	37.93 (25.82 to 50.73)
T12 PR24-48 RGT q12		39.47 (15.28 to 111.60)	41.91 (27.07 to 58.41)
T12 PR48 q8		22.83 (7.50 to 68.42)	23.46 (9.50 to 48.02)
SOF12 + PR12		28.14 (12.69 to 71.60)	29.43 (16.25 to 48.10)
SOF12 PR24-48 RGT		16.35 (5.15 to 54.29)	16.58 (7.04 to 33.26)
SIM12 PR24-48 RGT		15.80 (6.31 to 43.32)	15.88 (10.73 to 22.15)
B24 PR28-48 RGT		34.88 (13.61 to 96.00)	36.75 (24.58 to 49.77)
B44 PR48		29.69 (9.59 to 97.51)	31.45 (14.14 to 56.36)
PR24		18.77 (6.28 to 60.17)	19.35 (7.25 to 41.78)
SOF24 + RBV (low dose) 24		16.20 (5.41 to 53.93)	16.46 (6.32 to 34.47)
PAR/RIT12 + OMB12 + DAS12		6.55 (1.86 to 22.57)	5.97 (1.54 to 14.21)
PAR/RIT12 + OMB12 + DAS12 + RBV12		7.48 (2.73 to 22.52)	6.83 (2.42 to 16.13)
DCV12 + SOF12		1.95 (0.08 to 23.02)	0.90 (-1.62 to 19.42)
GRZ12 + ELB12		3.00 (0.70 to 13.65)	2.11 (-0.53 to 9.26)
GRZ12 + ELB12 + RBV12		12.95 (3.56 to 57.86)	12.98 (3.71 to 38.25)
GRZ12 + ELB12 (50 mg q.d.)		1.83 (0.15 to 16.06)	0.84 (-1.44 to 13.36)
GRZ18 + ELB18 (50 mg q.d.)		1.64 (0.03 to 37.67)	0.63 (-1.90 to 30.65)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		4.20 (0.33 to 48.82)	3.47 (-1.05 to 37.05)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		17.77 (1.36 to 114.00)	18.15 (0.44 to 79.32)
SOF12 + LDV12 + RBV12	SOF8 + LDV8 + RBV8	1.92 (0.43 to 8.73)	6.09 (-15.59 to 18.57)
SOF24 + LDV24 + RBV24		1.66 (0.37 to 7.74)	4.45 (-17.23 to 16.55)
T12 PR24-48 RGT q8		5.42 (1.30 to 23.69)	31.15 (8.06 to 45.89)
T12 PR24-48 RGT q12		5.98 (1.40 to 26.61)	34.88 (10.74 to 53.52)
T12 PR48 q8		3.46 (0.71 to 15.74)	16.56 (-6.96 to 41.12)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + PR12		4.23 (1.00 to 17.46)	22.19 (-0.07 to 41.23)
SOF12 PR24-48 RGT		2.47 (0.49 to 12.43)	9.87 (-13.07 to 27.96)
SIM12 PR24-48 RGT		2.39 (0.56 to 10.45)	9.53 (-12.43 to 18.58)
B24 PR28-48 RGT		5.31 (1.24 to 23.40)	29.89 (6.61 to 44.91)
B44 PR48		4.41 (1.00 to 22.22)	24.08 (-0.02 to 51.17)
PR24		2.81 (0.57 to 13.86)	12.45 (-10.06 to 36.32)
SOF24 + RBV (low dose) 24		2.39 (0.51 to 11.95)	9.62 (-11.48 to 28.90)
PAR/RIT12 + OMB12 + DAS12		0.98 (0.20 to 5.16)	-0.12 (-21.95 to 9.87)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.11 (0.23 to 5.32)	0.73 (-20.68 to 11.12)
DCV12 + SOF12		0.29 (0.01 to 3.93)	-4.38 (-26.15 to 13.41)
GRZ12 + ELB12		0.46 (0.08 to 2.84)	-3.64 (-25.39 to 4.95)
GRZ12 + ELB12 + RBV12		1.96 (0.37 to 11.74)	6.47 (-15.30 to 32.14)
GRZ12 + ELB12 (50 mg q.d.)		0.29 (0.02 to 2.69)	-4.52 (-25.75 to 6.86)
GRZ18 + ELB18 (50 mg q.d.)		0.25 (0.00 to 5.44)	-4.55 (-25.25 to 23.56)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.63 (0.04 to 8.80)	-2.25 (-24.00 to 30.85)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.50 (0.12 to 25.22)	10.89 (-16.59 to 70.87)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	0.87 (0.47 to 1.63)	-1.76 (-10.36 to 6.86)
T12 PR24-48 RGT q8		2.85 (1.41 to 5.75)	25.18 (9.11 to 39.71)
T12 PR24-48 RGT q12		3.13 (1.53 to 6.52)	29.05 (11.08 to 46.96)
T12 PR48 q8		1.80 (0.63 to 4.61)	10.75 (-7.35 to 36.37)
SOF12 + PR12		2.24 (1.01 to 4.90)	16.68 (0.17 to 35.92)
SOF12 PR24-48 RGT		1.29 (0.49 to 3.41)	3.89 (-10.96 to 22.14)
SIM12 PR24-48 RGT		1.24 (0.62 to 2.56)	3.23 (-8.85 to 12.47)
B24 PR28-48 RGT		2.76 (1.37 to 5.59)	23.88 (8.09 to 38.50)
B44 PR48		2.37 (0.90 to 5.97)	18.64 (-1.96 to 44.95)
PR24		1.50 (0.54 to 3.96)	6.67 (-8.86 to 29.21)
SOF24 + RBV (low dose) 24		1.29 (0.52 to 2.94)	3.92 (-9.17 to 21.09)
PAR/RIT12 + OMB12 + DAS12		0.52 (0.18 to 1.41)	-6.38 (-18.69 to 3.74)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.59 (0.20 to 1.61)	-5.48 (-17.98 to 5.93)
DCV12 + SOF12		0.15 (0.01 to 1.84)	-10.99 (-22.60 to 8.55)
GRZ12 + ELB12		0.24 (0.06 to 0.93)	-10.09 (-21.96 to -0.65)
GRZ12 + ELB12 + RBV12		1.05 (0.28 to 3.60)	0.60 (-15.16 to 26.93)
GRZ12 + ELB12 (50 mg q.d.)		0.14 (0.01 to 1.29)	-11.19 (-22.72 to 3.06)
GRZ18 + ELB18 (50 mg q.d.)		0.13 (0.00 to 2.62)	-11.03 (-22.63 to 18.96)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.34 (0.03 to 3.22)	-8.37 (-21.03 to 25.11)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.42 (0.11 to 7.23)	5.56 (-16.26 to 67.28)
T12 PR24-48 RGT q8	SOF24 + LDV24 + RBV24	3.26 (1.55 to 6.95)	26.85 (11.01 to 41.31)
T12 PR24-48 RGT q12		3.61 (1.68 to 7.81)	30.81 (12.93 to 48.58)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
T12 PR48 q8		2.05 (0.69 to 5.55)	12.39 (-5.68 to 37.60)
SOF12 + PR12		2.58 (1.09 to 5.84)	18.57 (1.64 to 37.65)
SOF12 PR24-48 RGT		1.49 (0.54 to 3.91)	5.65 (-9.09 to 23.79)
SIM12 PR24-48 RGT		1.43 (0.69 to 3.08)	5.01 (-6.65 to 13.95)
B24 PR28-48 RGT		3.17 (1.49 to 6.72)	25.71 (9.79 to 39.96)
B44 PR48		2.71 (0.99 to 6.81)	20.41 (-0.18 to 45.98)
PR24		1.72 (0.59 to 4.73)	8.38 (-7.63 to 31.35)
SOF24 + RBV (low dose) 24		1.47 (0.57 to 3.77)	5.52 (-7.83 to 23.68)
PAR/RIT12 + OMB12 + DAS12		0.59 (0.20 to 1.70)	-4.77 (-16.35 to 5.31)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.67 (0.23 to 1.91)	-3.75 (-15.77 to 7.32)
DCV12 + SOF12		0.17 (0.01 to 2.14)	-9.25 (-20.56 to 9.80)
GRZ12 + ELB12		0.28 (0.07 to 1.08)	-8.37 (-19.73 to 0.63)
GRZ12 + ELB12 + RBV12		1.18 (0.32 to 4.43)	2.04 (-12.55 to 28.64)
GRZ12 + ELB12 (50 mg q.d.)		0.17 (0.01 to 1.45)	-9.40 (-20.55 to 4.28)
GRZ18 + ELB18 (50 mg q.d.)		0.15 (0.00 to 2.97)	-9.25 (-20.76 to 20.50)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.39 (0.03 to 3.62)	-6.67 (-18.84 to 26.42)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.62 (0.12 to 8.77)	7.18 (-14.15 to 68.97)
T12 PR24-48 RGT q12	T12 PR24-48 RGT q8	1.10 (0.86 to 1.39)	4.01 (-5.28 to 14.44)
T12 PR48 q8		0.63 (0.26 to 1.39)	-14.18 (-34.28 to 12.70)
SOF12 + PR12		0.79 (0.41 to 1.45)	-8.33 (-26.85 to 14.37)
SOF12 PR24-48 RGT		0.46 (0.20 to 0.98)	-20.93 (-38.11 to -0.75)
SIM12 PR24-48 RGT		0.44 (0.28 to 0.69)	-21.95 (-35.50 to -9.08)
B24 PR28-48 RGT		0.97 (0.61 to 1.51)	-1.06 (-18.44 to 15.58)
B44 PR48		0.84 (0.37 to 1.63)	-6.21 (-28.48 to 20.82)
PR24		0.53 (0.20 to 1.18)	-18.05 (-36.01 to 6.10)
SOF24 + RBV (low dose) 24		0.46 (0.18 to 0.99)	-21.05 (-37.70 to -0.37)
PAR/RIT12 + OMB12 + DAS12		0.18 (0.09 to 0.35)	-31.57 (-41.90 to -21.31)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.20 (0.08 to 0.49)	-30.72 (-44.54 to -15.80)
DCV12 + SOF12		0.05 (0.00 to 0.56)	-36.01 (-49.83 to -14.68)
GRZ12 + ELB12		0.08 (0.02 to 0.29)	-35.49 (-48.84 to -21.27)
GRZ12 + ELB12 + RBV12		0.37 (0.12 to 1.10)	-24.45 (-40.91 to 3.43)
GRZ12 + ELB12 (50 mg q.d.)		0.05 (0.00 to 0.40)	-36.44 (-49.75 to -18.92)
GRZ18 + ELB18 (50 mg q.d.)		0.05 (0.00 to 0.82)	-36.04 (-49.60 to -6.39)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.12 (0.01 to 1.03)	-33.11 (-47.81 to 1.17)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.50 (0.04 to 2.14)	-19.38 (-42.41 to 42.07)
T12 PR48 q8	T12 PR24-48 RGT q12	0.58 (0.23 to 1.30)	-17.93 (-41.22 to 10.04)
SOF12 + PR12		0.71 (0.37 to 1.35)	-12.30 (-33.87 to 11.53)
SOF12 PR24-48 RGT		0.42 (0.18 to 0.91)	-24.76 (-44.93 to -3.01)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SIM12 PR24-48 RGT		0.40 (0.24 to 0.66)	-25.89 (-43.28 to -10.26)
B24 PR28-48 RGT		0.88 (0.54 to 1.44)	-5.08 (-25.24 to 13.53)
B44 PR48		0.76 (0.33 to 1.53)	-10.20 (-34.51 to 18.04)
PR24		0.48 (0.19 to 1.10)	-22.02 (-43.05 to 3.35)
SOF24 + RBV (low dose) 24		0.41 (0.16 to 0.92)	-25.01 (-44.92 to -2.66)
PAR/RIT12 + OMB12 + DAS12		0.17 (0.08 to 0.33)	-35.54 (-50.18 to -22.03)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.19 (0.08 to 0.46)	-34.56 (-52.15 to -17.31)
DCV12 + SOF12		0.05 (0.00 to 0.52)	-39.74 (-57.40 to -16.38)
GRZ12 + ELB12		0.08 (0.02 to 0.26)	-39.39 (-56.38 to -22.72)
GRZ12 + ELB12 + RBV12		0.33 (0.11 to 1.01)	-28.41 (-48.10 to 0.45)
GRZ12 + ELB12 (50 mg q.d.)		0.05 (0.00 to 0.37)	-40.26 (-57.35 to -20.68)
GRZ18 + ELB18 (50 mg q.d.)		0.04 (0.00 to 0.75)	-39.69 (-57.06 to -9.80)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.11 (0.01 to 0.95)	-36.76 (-54.97 to -1.86)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.45 (0.04 to 1.97)	-22.94 (-48.97 to 38.26)
SOF12 + PR12	T12 PR48 q8	1.24 (0.51 to 3.25)	5.96 (-21.00 to 29.42)
SOF12 PR24-48 RGT		0.74 (0.23 to 2.20)	-6.36 (-35.32 to 15.94)
SIM12 PR24-48 RGT		0.69 (0.32 to 1.73)	-7.52 (-32.75 to 8.39)
B24 PR28-48 RGT		1.54 (0.70 to 3.75)	13.11 (-14.07 to 32.81)
B44 PR48		1.31 (0.46 to 3.69)	7.63 (-23.58 to 37.48)
PR24		0.83 (0.26 to 2.63)	-4.13 (-31.26 to 23.29)
SOF24 + RBV (low dose) 24		0.72 (0.23 to 2.30)	-6.80 (-33.18 to 17.53)
PAR/RIT12 + OMB12 + DAS12		0.29 (0.10 to 0.95)	-17.32 (-42.01 to -0.65)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.33 (0.15 to 0.75)	-16.26 (-38.70 to -3.27)
DCV12 + SOF12		0.09 (0.00 to 0.69)	-21.05 (-42.38 to -5.60)
GRZ12 + ELB12		0.13 (0.03 to 0.59)	-21.10 (-45.89 to -5.02)
GRZ12 + ELB12 + RBV12		0.58 (0.16 to 2.22)	-10.19 (-36.21 to 18.00)
GRZ12 + ELB12 (50 mg q.d.)		0.08 (0.01 to 0.75)	-21.79 (-47.13 to -3.80)
GRZ18 + ELB18 (50 mg q.d.)		0.07 (0.00 to 1.64)	-21.28 (-46.69 to 11.56)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.19 (0.02 to 1.83)	-18.28 (-44.35 to 15.05)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.78 (0.06 to 4.27)	-5.10 (-37.45 to 55.76)
SOF12 PR24-48 RGT	SOF12 + PR12	0.58 (0.23 to 1.47)	-12.48 (-34.92 to 9.49)
SIM12 PR24-48 RGT		0.56 (0.33 to 1.00)	-13.45 (-31.93 to 0.04)
B24 PR28-48 RGT		1.23 (0.68 to 2.35)	7.07 (-14.82 to 25.87)
B44 PR48		1.06 (0.43 to 2.44)	1.88 (-24.35 to 30.56)
PR24		0.67 (0.28 to 1.51)	-9.92 (-29.41 to 12.18)
SOF24 + RBV (low dose) 24		0.57 (0.24 to 1.40)	-12.79 (-32.80 to 8.66)
PAR/RIT12 + OMB12 + DAS12		0.23 (0.09 to 0.60)	-23.28 (-42.78 to -7.89)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.26 (0.10 to 0.69)	-22.29 (-41.36 to -6.28)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV12 + SOF12		0.07 (0.00 to 0.68)	-27.20 (-46.90 to -7.98)
GRZ12 + ELB12		0.11 (0.03 to 0.38)	-26.89 (-46.68 to -12.23)
GRZ12 + ELB12 + RBV12		0.46 (0.14 to 1.64)	-15.74 (-38.93 to 13.87)
GRZ12 + ELB12 (50 mg q.d.)		0.06 (0.01 to 0.56)	-28.07 (-47.63 to -9.53)
GRZ18 + ELB18 (50 mg q.d.)		0.06 (0.00 to 1.15)	-27.47 (-47.39 to 3.67)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.15 (0.01 to 1.33)	-24.37 (-44.83 to 9.02)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.62 (0.06 to 3.10)	-11.39 (-38.14 to 49.86)
SIM12 PR24-48 RGT	SOF12 PR24-48 RGT	0.97 (0.44 to 2.25)	-0.57 (-18.41 to 11.35)
B24 PR28-48 RGT		2.12 (0.99 to 4.88)	19.83 (-0.41 to 36.64)
B44 PR48		1.82 (0.65 to 5.00)	14.51 (-10.26 to 42.36)
PR24		1.16 (0.35 to 3.50)	2.73 (-19.01 to 27.82)
SOF24 + RBV (low dose) 24		0.98 (0.32 to 2.96)	-0.28 (-20.05 to 20.53)
PAR/RIT12 + OMB12 + DAS12		0.40 (0.14 to 1.22)	-10.44 (-27.38 to 2.15)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.45 (0.15 to 1.41)	-9.46 (-27.05 to 4.32)
DCV12 + SOF12		0.11 (0.01 to 1.64)	-14.82 (-32.11 to 7.24)
GRZ12 + ELB12		0.18 (0.05 to 0.77)	-14.11 (-31.05 to -2.41)
GRZ12 + ELB12 + RBV12		0.79 (0.21 to 3.09)	-3.51 (-23.43 to 24.72)
GRZ12 + ELB12 (50 mg q.d.)		0.11 (0.01 to 1.00)	-15.10 (-32.35 to -0.04)
GRZ18 + ELB18 (50 mg q.d.)		0.10 (0.00 to 1.96)	-14.72 (-31.94 to 14.39)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.27 (0.02 to 2.44)	-11.69 (-30.54 to 21.17)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.11 (0.08 to 6.17)	1.83 (-25.50 to 64.84)
B24 PR28-48 RGT	SIM12 PR24-48 RGT	2.22 (1.39 to 3.45)	20.80 (7.74 to 34.47)
B44 PR48		1.91 (0.85 to 3.76)	15.58 (-2.91 to 41.18)
PR24		1.20 (0.49 to 2.67)	3.44 (-9.65 to 25.95)
SOF24 + RBV (low dose) 24		1.03 (0.42 to 2.29)	0.57 (-10.99 to 19.18)
PAR/RIT12 + OMB12 + DAS12		0.42 (0.17 to 0.99)	-9.82 (-17.21 to -0.22)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.47 (0.19 to 1.13)	-8.87 (-17.11 to 1.84)
DCV12 + SOF12		0.12 (0.01 to 1.29)	-14.30 (-21.66 to 4.36)
GRZ12 + ELB12		0.19 (0.06 to 0.67)	-13.57 (-20.51 to -4.78)
GRZ12 + ELB12 + RBV12		0.83 (0.26 to 2.57)	-2.85 (-15.06 to 23.50)
GRZ12 + ELB12 (50 mg q.d.)		0.12 (0.01 to 0.94)	-14.74 (-21.57 to -0.84)
GRZ18 + ELB18 (50 mg q.d.)		0.10 (0.00 to 1.79)	-14.57 (-21.72 to 13.59)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.27 (0.02 to 2.35)	-11.94 (-20.26 to 21.62)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.12 (0.10 to 5.03)	2.02 (-16.94 to 63.43)
B44 PR48	B24 PR28-48 RGT	0.86 (0.39 to 1.72)	-5.19 (-26.75 to 22.40)
PR24		0.55 (0.21 to 1.25)	-16.95 (-35.48 to 7.78)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV (low dose) 24		0.47 (0.19 to 1.04)	-19.86 (-36.97 to 1.20)
PAR/RIT12 + OMB12 + DAS12		0.19 (0.08 to 0.44)	-30.44 (-43.88 to -16.46)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.21 (0.09 to 0.51)	-29.49 (-43.76 to -14.49)
DCV12 + SOF12		0.05 (0.00 to 0.57)	-34.85 (-48.76 to -13.73)
GRZ12 + ELB12		0.09 (0.03 to 0.30)	-34.35 (-47.60 to -20.26)
GRZ12 + ELB12 + RBV12		0.37 (0.12 to 1.16)	-23.26 (-40.56 to 4.95)
GRZ12 + ELB12 (50 mg q.d.)		0.05 (0.00 to 0.42)	-35.30 (-48.91 to -17.05)
GRZ18 + ELB18 (50 mg q.d.)		0.05 (0.00 to 0.83)	-34.93 (-48.68 to -6.14)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.12 (0.01 to 1.05)	-31.95 (-46.87 to 1.59)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.52 (0.04 to 2.20)	-17.93 (-41.62 to 42.42)
PR24	B44 PR48	0.64 (0.22 to 1.75)	-11.56 (-38.74 to 15.20)
SOF24 + RBV (low dose) 24		0.55 (0.18 to 1.53)	-14.48 (-42.25 to 10.01)
PAR/RIT12 + OMB12 + DAS12		0.22 (0.08 to 0.64)	-25.07 (-50.61 to -6.31)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.25 (0.09 to 0.73)	-24.06 (-49.98 to -4.98)
DCV12 + SOF12		0.06 (0.00 to 0.66)	-29.21 (-54.81 to -7.09)
GRZ12 + ELB12		0.10 (0.03 to 0.41)	-28.85 (-54.23 to -10.58)
GRZ12 + ELB12 + RBV12		0.44 (0.12 to 1.55)	-17.36 (-45.16 to 12.33)
GRZ12 + ELB12 (50 mg q.d.)		0.06 (0.01 to 0.57)	-29.71 (-55.11 to -8.88)
GRZ18 + ELB18 (50 mg q.d.)		0.05 (0.00 to 0.98)	-28.94 (-55.06 to -0.64)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.15 (0.01 to 1.39)	-25.70 (-52.77 to 9.19)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.58 (0.05 to 2.95)	-12.48 (-44.93 to 48.00)
SOF24 + RBV (low dose) 24	PR24	0.85 (0.32 to 2.48)	-2.97 (-24.92 to 17.51)
PAR/RIT12 + OMB12 + DAS12		0.34 (0.11 to 1.09)	-13.23 (-35.99 to 0.93)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.40 (0.12 to 1.29)	-12.01 (-35.38 to 2.99)
DCV12 + SOF12		0.10 (0.00 to 1.23)	-17.28 (-40.38 to 3.08)
GRZ12 + ELB12		0.16 (0.04 to 0.68)	-16.81 (-39.75 to -3.32)
GRZ12 + ELB12 + RBV12		0.69 (0.18 to 2.92)	-6.05 (-31.50 to 23.44)
GRZ12 + ELB12 (50 mg q.d.)		0.09 (0.01 to 1.00)	-17.85 (-40.31 to 0.04)
GRZ18 + ELB18 (50 mg q.d.)		0.09 (0.00 to 1.63)	-17.28 (-40.26 to 10.07)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.23 (0.02 to 2.16)	-14.48 (-37.15 to 17.96)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.95 (0.07 to 5.25)	-1.04 (-30.78 to 59.45)
PAR/RIT12 + OMB12 + DAS12	SOF24 + RBV (low dose) 24	0.40 (0.13 to 1.27)	-10.30 (-28.34 to 2.50)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.45 (0.15 to 1.60)	-9.46 (-27.79 to 5.39)
DCV12 + SOF12		0.11 (0.01 to 1.61)	-14.61 (-32.76 to 6.38)
GRZ12 + ELB12		0.19 (0.05 to 0.76)	-14.05 (-32.06 to -2.26)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12 + RBV12		0.81 (0.22 to 3.24)	-3.26 (-23.95 to 24.49)
GRZ12 + ELB12 (50 mg q.d.)		0.11 (0.01 to 1.10)	-15.05 (-33.41 to 1.13)
GRZ18 + ELB18 (50 mg q.d.)		0.11 (0.00 to 2.18)	-14.58 (-34.03 to 15.24)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.27 (0.02 to 2.77)	-11.71 (-31.59 to 22.15)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.11 (0.08 to 6.02)	1.81 (-26.69 to 63.27)
PAR/RIT12 + OMB12 + DAS12 + RBV12	PAR/RIT12 + OMB12 + DAS12	1.14 (0.35 to 3.65)	0.91 (-8.65 to 11.40)
DCV12 + SOF12		0.28 (0.01 to 3.47)	-4.52 (-13.38 to 13.41)
GRZ12 + ELB12		0.46 (0.11 to 2.01)	-3.70 (-12.03 to 4.48)
GRZ12 + ELB12 + RBV12		1.99 (0.53 to 7.75)	6.82 (-5.49 to 32.46)
GRZ12 + ELB12 (50 mg q.d.)		0.27 (0.02 to 2.66)	-4.77 (-13.41 to 8.36)
GRZ18 + ELB18 (50 mg q.d.)		0.25 (0.01 to 4.70)	-4.69 (-13.37 to 23.08)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.65 (0.05 to 6.66)	-2.26 (-11.74 to 30.95)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.69 (0.22 to 14.61)	11.78 (-7.57 to 72.61)
DCV12 + SOF12	PAR/RIT12 + OMB12 + DAS12 + RBV12	0.27 (0.01 to 2.45)	-5.06 (-14.95 to 11.32)
GRZ12 + ELB12		0.40 (0.10 to 1.78)	-4.52 (-14.34 to 3.90)
GRZ12 + ELB12 + RBV12		1.76 (0.47 to 7.12)	5.95 (-7.33 to 32.41)
GRZ12 + ELB12 (50 mg q.d.)		0.25 (0.02 to 2.28)	-5.64 (-15.41 to 6.93)
GRZ18 + ELB18 (50 mg q.d.)		0.21 (0.00 to 4.91)	-5.59 (-15.52 to 24.45)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.59 (0.04 to 5.53)	-3.02 (-13.44 to 29.56)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		2.33 (0.18 to 13.28)	11.16 (-9.40 to 71.87)
GRZ12 + ELB12	DCV12 + SOF12	1.67 (0.11 to 41.45)	1.08 (-17.40 to 8.66)
GRZ12 + ELB12 + RBV12		7.03 (0.49 to 165.10)	11.24 (-8.68 to 36.79)
GRZ12 + ELB12 (50 mg q.d.)		0.93 (0.02 to 43.14)	-0.08 (-18.62 to 12.45)
GRZ18 + ELB18 (50 mg q.d.)		0.80 (0.01 to 47.28)	-0.23 (-18.99 to 29.37)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		2.32 (0.06 to 118.60)	2.18 (-17.13 to 36.32)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		9.12 (0.31 to 303.00)	15.59 (-9.70 to 78.19)
GRZ12 + ELB12 + RBV12	GRZ12 + ELB12	4.33 (0.84 to 22.08)	10.41 (-1.18 to 35.90)
GRZ12 + ELB12 (50 mg q.d.)		0.59 (0.04 to 6.20)	-1.15 (-8.51 to 11.69)
GRZ18 + ELB18 (50 mg q.d.)		0.54 (0.01 to 11.41)	-1.27 (-8.30 to 27.42)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.42 (0.10 to 17.94)	1.27 (-6.68 to 34.31)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		5.78 (0.38 to 41.64)	15.47 (-3.13 to 76.15)
GRZ12 + ELB12 (50 mg q.d.)	GRZ12 + ELB12 + RBV12	0.14 (0.01 to 0.88)	-11.30 (-33.52 to -1.02)
GRZ18 + ELB18 (50 mg q.d.)		0.13 (0.00 to 2.18)	-10.95 (-34.66 to 14.80)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.34 (0.02 to 2.99)	-8.11 (-32.28 to 22.72)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.35 (0.11 to 7.18)	4.91 (-22.79 to 60.68)
GRZ18 + ELB18 (50 mg q.d.)	GRZ12 + ELB12 (50 mg q.d.)	0.92 (0.03 to 11.50)	-0.10 (-8.15 to 24.24)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		2.41 (0.35 to 16.12)	2.24 (-3.84 to 32.29)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		9.16 (1.66 to 49.70)	16.59 (0.81 to 70.96)
GRZ12 + ELB12 (50 mg q.d.) + RBV12	GRZ18 + ELB18 (50 mg q.d.)	2.56 (0.20 to 86.72)	1.95 (-14.66 to 28.92)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		8.92 (1.16 to 331.80)	15.76 (0.41 to 66.87)
GRZ18 + ELB18 (50 mg q.d.) + RBV18	GRZ12 + ELB12 (50 mg q.d.) + RBV12	3.55 (0.83 to 24.74)	12.58 (-1.43 to 58.87)
Random effect model	Residual deviance	71.41 vs. 75 data points	
	Deviance information criteria	411.391	
Fixed effect model	Residual deviance	72.11 vs. 75 data points	
	Deviance information criteria	410.294	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.